compulsory licensing

This page shows the latest compulsory licensing news and features for those working in and with pharma, biotech and healthcare.

Roche blocks Herceptin biosimilar in India

Herceptin has been an intellectual property (IP) battleground in India, with threats of compulsory licensing eventually causing Roche to relinquish its patents on the drug in India, clearing the path for

Latest news

Pharma slammed for undermining South African IP reforms

life-saving medicines through compulsory licensing and other means.
Biocon plans February launch for first biosimilar Herceptin

It has been suggested the company took the decision after it emerged it was facing compulsory licensing for Herceptin in India on the grounds of public need, a path which opened
Pharma should not ignore India

It’s complicated, but multinational pharma cannot ignore a market with one billion plus people
Roche loses Herceptin patents in India

Compulsory licensing threat looms. A much bigger threat to Herceptin in India is that of compulsory licensing, which was used to clear the path for low-cost versions of Bayer's ... There was some positive news for Roche last month after India's
Pharma waits for Glivec patent verdict in India

Meanwhile, other patented medicines have been subject to compulsory licensing in India on the principle of public health need.

More from news
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest Intelligence

Stress testing for the perfect compliance storm

Some markets have introduced charges for access to state healthcare premises or compulsory licensing, and some HCOs are now seeking direct support either as financial donations or as medical education, patient
Intellectual property threats in the BRIC markets

However, China also passed the “ Measures for the Compulsory Licensing of Patent Implementation” law in May 2012. ... There are two ways of interpreting recent trends in compulsory licensing and IP loss.
Building BRICs: pharma's key emerging markets are becoming giants

Others, such as Roche, are partnering with local manufacturers under out-licensing agreements. ... The government has issued high-profile proposals around compulsory licensing and price-capping.

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Home based, Principal Medical Writer, Medical Communications: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Editorial Team Leader, Medical Communications: Excellent package

Business Unit Head, Medical Communications, London: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Account Manager: Competitive salary commensurate with experience

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Editorial Director – Medical Education (MedComms): Neg

Client Services Director – Healthcare Advertising - London: Neg

Account Manager: £40, 000 - £45, 000 benefits

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Senior Medical Writer, Medical Communications: Excellent package

Home based, Chief Medical Writer, Medical Communications: Excellent package

Client Services Director - Med Comms: Great salary and bebefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Delivery Manager/ Head of Delivery – Executive Search: Neg

Subscribe to our email news alerts

PMHub

Add my company

Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....